These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18713784)

  • 1. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
    Marotte H; Gineyts E; Miossec P; Delmas PD
    Ann Rheum Dis; 2009 Jul; 68(7):1197-200. PubMed ID: 18713784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
    Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
    van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
    Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.
    Garnero P; Piperno M; Gineyts E; Christgau S; Delmas PD; Vignon E
    Ann Rheum Dis; 2001 Jun; 60(6):619-26. PubMed ID: 11350852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
    Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
    J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
    Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
    Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.
    Gineyts E; Mo JA; Ko A; Henriksen DB; Curtis SP; Gertz BJ; Garnero P; Delmas PD
    Ann Rheum Dis; 2004 Jul; 63(7):857-61. PubMed ID: 15194584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
    Marotte H; Pallot-Prades B; Grange L; Gaudin P; Alexandre C; Miossec P
    Arthritis Res Ther; 2007; 9(3):R61. PubMed ID: 17597527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy.
    Lemarechal H; Allanore Y; Chenevier-Gobeaux C; Kahan A; Ekindjian OG; Borderie D
    Clin Chim Acta; 2006 Oct; 372(1-2):147-53. PubMed ID: 16716286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
    Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
    Mod Rheumatol; 2009; 19(3):273-82. PubMed ID: 19452245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.